Skip to main content
OpenTrials
Completed

NCT Number: NCT02614638

Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy

The main objective of this study is to evaluate the impact of the presence of a pharmacy technician in a care unit (Hepato-Gastroenterology Department) on detected medication errors.

This is a before-after study consisting of three sequential phases:

Month 1: one month of observation of what is happening in the department Month 2: one month wash out period Month 3: active participation of a pharmacy technician in the department

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHRU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, 30029, France

About this study

The secondary objectives of this study are:

A- To assess the impact of the presence of a pharmacy technician on the ratio of the number of patients with at least one medication error / number of included patients hospitalized in the service.

B- To characterize detected medication errors.

C- To identify and evaluate the potential causes of medication errors.

D- To evaluate whether the presence of a pharmacy technician reduces nursing time spent on medication management.

E- To evaluate the economic impact of the presence of a pharmacy technician.

F- To evaluate the acceptability of the intervention by the nursing staff and pharmacy technicians using questionnaires.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is hospitalized in the Hepato-Gastroenterology Department of the Nîmes University Hospital

Exclusion criteria

  • The patient is under judicial protection
  • The patient, or his/her legal guardian, expresses opposition to participation in the study
  • It is impossible to correctly inform the patient

Treatment and study plan

One month of department-wide observation

Other

A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.

Pharm Tech participates in department

Other

Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.

Primary outcomes

  1. The following ratio (relative units): Number of medication errors / number of medications administered and omitted from among all those listed on the prescription for admission

    Time frame: 5 days

    Primary Outcome Measure as given in protocol: Number of medication errors / number of medications administered and omitted from among all those listed on the prescription for admission (during month 1 versus during month 3).

Secondary outcomes

  1. Number of patients with at least one medication error / total number of hospitalized patients included in the service

    Time frame: 5 days

  2. For each medication error: the name of the drug

    Time frame: 5 days

  3. For each medication error: the type of error

    Time frame: 5 days

    Errors are classifies as one of the following types:

    Omission; Drug; Dosage form; Expired or damaged drug; Dose; Concentration; Frequency of administration; Administration technique; Route of Administration; Rate of administration; Duration of administration; Administration Time; Patient; Drug interaction.

  4. For each medication error: the severity index

    Time frame: 5 days

  5. For each medication error: when (which step) the error occurred during the drug pathway

    Time frame: 5 days

    The considered steps are:

    Writing the prescription Medical decision for the prescription Transcription Pharmaceutical analysis Deliverance Preparation / reconstitution Pillbox Administration Procurement Storage Compliance Therapeutic and clinical follow-up

  6. For each medication error: the evolution of the adverse drug event, if occurred

    Time frame: 5 days

  7. For each medication error: the criticality of the error

    Time frame: 5 days

    Criticality is graded according to the following classes:

    • C: no potential harm to the patient;
    • D: treatment or increased monitoring without harm to the patient
    • (E to I): potential harm to the patient

    3E: treatment or surgery with temporary harm 3F: longer duration of hospitalization with temporary harm 3G: permanent harm 3H: involving a life-threatening harm 3I: death

    Criticality is determined by the concordance of two, independent expert opinions; or, in case of discordance, the concordance of 2 out 3 expert opinions.

  8. The potential causes of medication errors

    Time frame: 5 days

  9. The average number of interruptions per hour during preparation or administration of drug doses by nurses

    Time frame: 5 days

  10. The number of patients for whom personal treatments were managed by the nursing staff on admission / number of patients who brought their personal treatments to the care unit

    Time frame: 5 days

  11. The number of patients for whom personal treatments were returned by the nursing staff at hospital discharge / number of patients who brought their personal treatments to the care unit

    Time frame: 5 days

  12. Nursing staff time dedicated to: the preparation of individual doses

    Time frame: 5 days

  13. Nursing staff time dedicated to: ordering health products

    Time frame: 5 days

  14. Nursing staff time dedicated to: stock management and exceptional orders

    Time frame: 5 days

  15. Nursing staff time dedicated to: the delivery, receipt and storage of health products

    Time frame: 5 days

  16. Nursing staff time dedicated to: cabinet inventories

    Time frame: 5 days

  17. Nursing staff time dedicated to: the management of expired drugs

    Time frame: 5 days

  18. The number of calls made to the central pharmacy

    Time frame: 5 days

  19. Staff time dedicated to managing exceptional requests

    Time frame: 5 days

  20. The number of drugs consumed

    Time frame: 5 days

  21. The number of medical devices consumed

    Time frame: 5 days

  22. The number of immobilized drugs

    Time frame: 5 days

  23. The number of immobilized medical devices

    Time frame: 5 days

  24. The cost of adverse drug events care

    Time frame: 5 days

  25. Care staff satisfaction questionnaire

    Time frame: 5 days

  26. Pharmacy technician satisfaction questionnaire

    Time frame: 5 days

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy in the Hepato-Gastroenterology Department of the Nîmes University Hospital

Acronym: OPTI-PP

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Nov 25, 2015
Registry last updated
Feb 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.